Samsung Bioepis and Epis NexLab Sign Research Collaboration and License Agreement with G2GBIO to Develop Novel Assets Including Long-acting Semaglutide

Samsung Bioepis to receive exclusive license to develop and commercialize two novel assets including long-acting semaglutide using G2GBIO's proprietary microsphere technology -- Epis NexLab, a sister ...
Contract Pharma

Samsung Bioepis, Epis NexLab Partner with G2GBIO to Develop Novel Semaglutide Assets

Samsung Bioepis and Epis NexLab have entered a research collaboration and license agreement with G2GBIO to develop novel assets based on G2GBIO’s proprietary microsphere technology.
ksn.com

NEXTBIOMEDICAL Secures FDA Breakthrough Device Designation for Innovative Resorbable Microsphere 'Nexsphere-F™'

SEOUL, South Korea, March 6, 2025 /PRNewswire/ -- NEXTBIOMEDICAL CO., LTD, a leading developer of cutting-edge Devices, announced that its groundbreaking product 'Nexsphere-F™,' a resorbable ...
News Medical

Exploring common methods for microsphere formulation in drug delivery

Polymeric microspheres play a pivotal role in advancing high-potency therapeutics, offering controlled release capabilities. Significant progress in biotechnology and combinatorial chemistry has ...